.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, clients along with metastatic intestinal tumors that acquired biomarker-matched therapies based on distributing growth DNA profiling revealed a more significant medical advantage than those acquiring unequaled treatment.